Rapid Antibody Gene-to-Drug Substance Sell Sheet
Abstract: Catalent’s Rapid Antibody Gene‑to‑Drug Substance program provides an accelerated, end‑to‑end pathway to move traditional monoclonal antibody programs from gene construct to GMP drug substance in as little as eight months. Built on the GPEx® Lightning cell line development platform and supported by proven process development and U.S.-based GMP manufacturing, this integrated offering delivers predictable performance, analytical readiness, and seamless scale-up to clinical supply. The platform is designed to reduce development risk, streamline execution, and help emerging biopharma teams achieve IND and first‑in‑human milestones with confidence.